Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (February 2017)
21 slides from Noxopharm's investor presentation, Feb 21, 2017
Slide 1: ASX CEO Presentation, Feb 2017
For personal use only ASX CEO Presentation, Feb 2017 ASX: NOX 1
Slide 2: Survival rates remain poor for many cancers
After 45 After 10-year 45 Years years of ‘the of Cytotoxic war on cancer’….... Chemotherapy... For personal use only survival rates remain poor for many cancers • Pancreas • Lung Little or no • Brain progress • Head and neck made in • Oesophagus survival outcome for • Stomach cancers of: • Cervix •
Slide 3: All cells have a master switch that determines death or survival
All cells have a master switch that determines their death or survival For personal use only Pro-survival Pro-death • cell growth • cell division Ceramide Sphingosine - • cell migration 1-phosphate • resistance to drugs and radiotherapy 3
Slide 4: Cancer cells lock master switch ON (survival mode)
Cancer cells lock master switch ON (survival mode). For personal use only Pro-survival Ceramide Sphingosine - 1-phosphate Key sub-switches overactive Akt PI3K PARP1 4
Slide 5: Drugs directed at master switch or sub-switches have proven too toxic
Drugs directed at master switch or sub-switches have proven to be too toxic For personal use only Sphingosine Drugs not Switches are selective the samefor tumourcells in normal cellsand cancer cells -1- phosphate Survival switches in normal cells also knocked out Akt Dosage needs to be kept low to a
Slide 6: Idronoxil: first drug to knock out master switch in cancer cells only
IDRONOXIL. First drug to knock out master switch in CANCER CELLS ONLY For personal use only Master switch knocked out Drugs not All sub-switches knocked out PARP1 Cancer cells (including highly resistant Ceramide Sphingosine - cells) now killed by minute amounts of 1-phosphate chemotherapy drugs No
Slide 7: Idronoxil
Idronoxil For personal use only NOT intended to be used as a monotherapy (single agent chemotherapy) USE is to make existing chemotherapies/radiotherapies work better Does NOT inflict damage on cancer cell. Makes cell unable to repair damage inflicted by other therapies 7 Source: Brown D et al (2008
Slide 8: Idronoxil as a chemo-sensitiser
Idronoxil as a chemo-sensitiser For personal use only Sensitivity to chemotherapies increased >2,000x times Cisplatin Carboplatin Overturns resistance to all Paclitaxel Docetaxel major cytotoxic drugs Gemcitabine Doxrubicin Topotecan Overturns resistance in all Ovarian Melanoma forms of cancers test
Slide 9: Idronoxil: History
Idronoxil: History For personal use only • 20 clinical trials Molecule • > 400 patients discovered Potent chemo- • late-stage cancer sensitising • Phase 3 trial ovarian cancer effect confirmed 1992 1998 1999 …...................................2009 9
Slide 10: Idronoxil subject to extensive Phase 2 metabolism
Idronoxil subject to extensive Phase 2 metabolism For personal use only + S S Body attaches sugar Drug now INACTIVE Proprietary formulation S Body unable to attach sugar Drug now ACTIVE 10
Slide 11: IP position
IP position For personal use only Idronoxil Structure not patentable. First described by G. Kelly in 1994 Patent lodgements v Innovative formulation designed to block Phase 2 metabolism v Clinical uses (eg ability to cross blood-brain barrier) IP strategy IP around second- and third-generation compo
Slide 12: Clinical Program
Clinical Program For personal use only Cytotoxic chemotherapy Radiotherapy 12
Slide 13: Key Clinical Trial Objectives
Key Clinical Trial Objectives For personal use only Patients with late-stage cancers that have failed to respond to standard therapies and have no remaining standard treatment options Clinical studies #1. Use NOX66 (+ chemotherapy and/or radiotherapy) to produce significant anti-cancer responses whe
Slide 14: Phase 1/Phase 2 Clinical Trial Program
AIM: • to have proof-of-concept by end-2017 For personal use only • decision on indication for registration studies by end of 1Q-2018 ProposedPhase 1/Phase clinical study2 Clinical timelineTrial Program 1Q 2017 2Q 2017 3Q 2017 4Q 2017 1Q 2018 NOX66 – 001 + chemotherapy Phase 1a Phase 1b Phase 2a Pha
Slide 15: Our objective
Our objective For personal use only To bring to market a proprietary drug that: q overturns resistance mechanisms to standard chemotherapy and radiotherapy q that works in most (if not all) forms of cancer q that provides effective and durable responses in early- or late-stage disease q that allows
Slide 16: Fastest route to market
? Fastest route to market For personal use only ? Best commercial strategy • chemotherapy 1. Best treatment combination • radiotherapy 2. Best purpose of use • Make standard dose work better • Allow use of lower dose 3. Optimal cancer type • Prostate, lung, other 16
Slide 17: Key metrics
Key metrics For personal use only Shares outstanding 75M : 40M free; 35M escrowed (July 2019) Other 22.5M options ($0.30) (2018) Cash position AU$ 6.0M IPO (9 Aug 2016) AU$ 4.5M (Jan 2017) Market cap $43M 17
Slide 18: News Flow
News Flow For personal use only Clinical Program 5 Phase 1b studies: progressive updates over 2017 as key safety and efficacy milestones achieved Pre-Clinical Program 5 R&D studies: brain cancer program announced; other 4x by mid-2017 Other • IP (patent lodgements) • Research collaborations • Shareh
Slide 19: Key Messages
For personal use only Key Messages Resistance to chemotherapy/radiotherapy remains the most pressing and largest problem facing patients No drug has come to market that successfully treats this problem NOX66 IS FIRST DRUG TO OVERTURN RESISTANCE MECHANISMS IN CANCER CELLS ONLY WE EXPECT TO KNOW WITHI
Slide 20: Disclaimer
For personal use only Disclaimer 4 This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or
Slide 21: Contact
For personal use only Contact Dr Graham Kelly Chief Executive Officer graham.kelly@noxopharm.com 21